Short description
Biodel is a biopharmaceutical company developing and commercializing therapeutics for the treatment of diabetes.
Description
Biodel Inc. (Biodel) is a development-stage company. The Company is a biopharmaceutical company focused on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta. It has formulated Linjeta as rapid-acting mealtime insulin for the treatment of patients with Type I and Type II diabetes. Earlier stage product candidates include follow-on and second generation rapid-acting mealtime insulins or insulin analogs, VIAtab, a sublingual tablet formulation of insulin, a line of basal insulins, and a formulation of glucagon.
Last funding
No Way
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Danbury, Connecticut, United States, North America
Founded on
January 1, 2003
Exited on
May 11, 2007
Went public on
May 11, 2007
Delisted on
November 3, 2016
Stock symbol
BIOD
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$34056 - 789030
Sign in for full access
Investors
Uh Ohhhh, Noaccess
Sign in for full access
Founders
Solomon S. Steiner